A coronavirus patient has expressed optimism at the prospect of being successfully vaccinated against the novel disease after participating in a trial.
David Rach was the first person injected during a trial at the University of Maryland School of Medicine to test a potential vaccine produced by Pfizer – with results proving ‘positive’
“It’s promising. Even despite being in the low dose group, I generated higher Sars-COV-2 Spike Protein RBD specific antibodies than the levels that are seen in the recovering COVID patients’ samples,” he said.
“There is a component of relief seeing that it’s actually producing results, that the vaccine is producing antibodies,” he told abc7 WJLA.
“It’s exciting…in the promise of a vaccine by next year and life returning to a semblance of normal.”
US pharmaceutical giant Pfizer – which has produced the potential vaccine alongside German firm BioNTech – reports the trial appears to be proving successful.
The manufacturers are gearing up to mass-produce the vaccine if it definitively proves effective – with 100 million doses expected by the end of the year.
